FMC Corporation Reports Steep Revenue Decline Amid Macro Challenges
Event summary
- FMC Corporation reported a 17% year-over-year revenue decline in Q2 2026, with organic revenue down 22%.
- Adjusted EBITDA fell 26% to $153 million, exceeding the high end of guidance.
- The company expects full-year revenue to decline by 7% at the midpoint, with Adjusted EBITDA down 23%.
- FMC announced plans to generate approximately $1 billion in proceeds for debt reduction through asset sales and licensing agreements.
The big picture
FMC Corporation's Q2 2026 results highlight the challenges facing agricultural chemical companies amid a tough macroeconomic environment. The company is focusing on debt reduction and portfolio optimization, but its ability to execute these strategies will be critical in determining long-term growth prospects. The strategic review concluded with a focus on improving competitiveness and advancing technology-driven solutions.
What we're watching
- Execution Risk
- The pace at which FMC can complete its planned asset sales and licensing agreements will determine its ability to reduce debt and stabilize financial performance.
- Market Conditions
- Whether the company's adjusted guidance reflects a sustainable turnaround or further downside risk amid challenging macroeconomic conditions.
- Portfolio Transition
- How effectively FMC can manage the post-patent transition for Rynaxypyr® while accelerating growth in new active ingredients.
Related topics